M. Ezra Friedberg - Feb 21, 2024 Form 4 Insider Report for Chromocell Therapeutics Corp (CHRO)

Role
Director
Signature
/s/ Ezra Friedberg
Stock symbol
CHRO
Transactions as of
Feb 21, 2024
Transactions value $
$99,077
Form type
4
Date filed
2/23/2024, 05:12 PM
Previous filing
Feb 15, 2024
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRO Common Stock Options Exercise $65.5K +13.6K +2.73% $4.80* 514K Feb 21, 2024 Balmoral Financial Group LLC F1, F2
transaction CHRO Common Stock Options Exercise $33.6K +6.99K +1.36% $4.80* 521K Feb 21, 2024 Balmoral Financial Group LLC F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRO Secured Convertible Promissory Note Conversion of derivative security -65.5K -100% 0 Feb 21, 2024 Common Stock 13.6K $4.80 Balmoral Financial Group LLC F1, F2
transaction CHRO Secured Convertible Promissory Note Conversion of derivative security -33.1K -100% 0 Feb 21, 2024 Common Stock 6.99K $4.80 Balmoral Financial Group LLC F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).
F2 Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.
F3 Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.